CV Sciences Inc (0VE.BE)
| Previous close | 0.0325 |
| Open | 0.0325 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0325 - 0.0325 |
| 52-week range | 0.0321 - 0.1174 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 15 May 2023 - 19 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
CV Sciences, Inc. Reports Fiscal Year-End 2022 Financial Results
CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the year and quarter ended December 31, 2022.
- PR Newswire
CV SCIENCES, INC. TO ANNOUNCE YEAR END AND FOURTH QUARTER 2022 RESULTS ON MARCH 29, 2023
CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the year and fourth quarter ended December 31, 2022, before the stock market opens on Wednesday, March 29, 2023. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m.
- PR Newswire
CV Sciences Receives Formal Notice of Patent Issuance from Japan Patent Office for Formulations Containing Cannabidiol (CBD) and Nicotine for Treating Smokeless Tobacco Addiction
CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, today announced that recently the Company received its formal Certificate of Grant from the Japan Patent Office (JPO) for its patent application 7216697.
